Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Type I interferon suppresses tumor growth through activating the STAT3-granzyme B pathway in tumor-infiltrating cytotoxic T lymphocytes
Chunwan Lu, John D. Klement, Mohammed L. Ibrahim, et al.
Journal for ImmunoTherapy of Cancer (2019) Vol. 7, Iss. 1
Open Access | Times Cited: 116

Showing 1-25 of 116 citing articles:

JAK-STAT Signaling: A Double-Edged Sword of Immune Regulation and Cancer Progression
Katie L. Owen, Natasha K. Brockwell, Belinda S. Parker
Cancers (2019) Vol. 11, Iss. 12, pp. 2002-2002
Open Access | Times Cited: 540
Inflammatory Cytokines in Cancer: Comprehensive Understanding and Clinical Progress in Gene Therapy
Tianxia Lan, Li Chen, Xiawei Wei
Cells (2021) Vol. 10, Iss. 1, pp. 100-100
Open Access | Times Cited: 175
Type I Interferon (IFN)-Regulated Activation of Canonical and Non-Canonical Signaling Pathways
Candice Mazewski, Ricardo E. Perez, Eleanor N. Fish, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 144
Deregulation of HLA-I in cancer and its central importance for immunotherapy
Ahmet Hazini, Kerry Fisher, Leonard W. Seymour
Journal for ImmunoTherapy of Cancer (2021) Vol. 9, Iss. 8, pp. e002899-e002899
Open Access | Times Cited: 143
Opposing Roles of Type I Interferons in Cancer Immunity
Giselle M. Boukhaled, Shane M. Harding, David G. Brooks
Annual Review of Pathology Mechanisms of Disease (2020) Vol. 16, Iss. 1, pp. 167-198
Open Access | Times Cited: 141
Tumor PD-L1 engages myeloid PD-1 to suppress type I interferon to impair cytotoxic T lymphocyte recruitment
John D. Klement, Priscilla S. Redd, Chunwan Lu, et al.
Cancer Cell (2023) Vol. 41, Iss. 3, pp. 620-636.e9
Open Access | Times Cited: 74
Type I interferon and cancer
Peter Holíček, Emma Guilbaud, Vanessa Klapp, et al.
Immunological Reviews (2023) Vol. 321, Iss. 1, pp. 115-127
Open Access | Times Cited: 45
Chromosomal instability as a driver of cancer progression
Xuelan Chen, Albert S. Agustinus, Jun Li, et al.
Nature Reviews Genetics (2024) Vol. 26, Iss. 1, pp. 31-46
Closed Access | Times Cited: 22
<p>Toll-Like Receptor 9 Agonists in Cancer</p>
Lilit Karapetyan, Jason J. Luke, Diwakar Davar
OncoTargets and Therapy (2020) Vol. Volume 13, pp. 10039-10061
Open Access | Times Cited: 107
Type I and II Interferons in the Anti-Tumor Immune Response
Sarah E. Fenton, Diana Saleiro, Leonidas C. Platanias
Cancers (2021) Vol. 13, Iss. 5, pp. 1037-1037
Open Access | Times Cited: 95
Molecular Aspects and Future Perspectives of Cytokine-Based Anti-cancer Immunotherapy
Daria S. Chulpanova, Kristina V. Kitaeva, Andrew R. Green, et al.
Frontiers in Cell and Developmental Biology (2020) Vol. 8
Open Access | Times Cited: 92
Viral infection of cells within the tumor microenvironment mediates antitumor immunotherapy via selective TBK1-IRF3 signaling
Michael C. Brown, Mubeen Mosaheb, Malte Mohme, et al.
Nature Communications (2021) Vol. 12, Iss. 1
Open Access | Times Cited: 63
STAT3 gain-of-function mutations connect leukemia with autoimmune disease by pathological NKG2Dhi CD8+ T cell dysregulation and accumulation
Etienne Masle‐Farquhar, Katherine Jackson, Timothy J. Peters, et al.
Immunity (2022) Vol. 55, Iss. 12, pp. 2386-2404.e8
Open Access | Times Cited: 47
ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy
Jingjing Wei, Di Wu, Yu Shao, et al.
Journal of Controlled Release (2022) Vol. 347, pp. 68-77
Closed Access | Times Cited: 41
Clonally expanded CD38 hi cytotoxic CD8 T cells define the T cell infiltrate in checkpoint inhibitor–associated arthritis
Runci Wang, Anvita Singaraju, Kathryne E. Marks, et al.
Science Immunology (2023) Vol. 8, Iss. 85
Open Access | Times Cited: 37
Long-Read Sequencing Reveals Rapid Evolution of Immunity- and Cancer-Related Genes in Bats
Armin Scheben, O. Ramos, Melissa Kramer, et al.
Genome Biology and Evolution (2023) Vol. 15, Iss. 9
Open Access | Times Cited: 32
Interplay between Signaling Pathways and Tumor Microenvironment Components: A Paradoxical Role in Colorectal Cancer
Sonia Ben Hamouda, Khadija Essafi‐Benkhadir
International Journal of Molecular Sciences (2023) Vol. 24, Iss. 6, pp. 5600-5600
Open Access | Times Cited: 24
SOCS1 is a critical checkpoint in immune homeostasis, inflammation and tumor immunity
Grace M. Bidgood, Narelle Keating, Karen Doggett, et al.
Frontiers in Immunology (2024) Vol. 15
Open Access | Times Cited: 15
Type I interferon signaling induces melanoma cell-intrinsic PD-1 and its inhibition antagonizes immune checkpoint blockade
Julia Holzgruber, Christina Martins, Zsófi Kulcsár, et al.
Nature Communications (2024) Vol. 15, Iss. 1
Open Access | Times Cited: 11
Investigating the role of inflammatory cytokines in mediating the effect of gut microbiota on gastrointestinal cancers: a mendelian randomization study
Wentao Liu, Xinwen Hu, Y.M. Choy, et al.
Gastric Cancer (2025)
Closed Access | Times Cited: 1
An overview of the nutritional composition, bioactivities and applications of Chinese yam (Dioscoreas Oppositae)
Great Iruoghene Edo, Susan Chinedu Nwachukwu, Patrick Othuke Akpoghelie, et al.
Deleted Journal (2025)
Closed Access | Times Cited: 1
Advances in Anti-Cancer Immunotherapy: Car-T Cell, Checkpoint Inhibitors, Dendritic Cell Vaccines, and Oncolytic Viruses, and Emerging Cellular and Molecular Targets
Emilie Louise Alard, Aura-Bianca Butnariu, Marta Grillo, et al.
Cancers (2020) Vol. 12, Iss. 7, pp. 1826-1826
Open Access | Times Cited: 66
Targeting STING in cancer: Challenges and emerging opportunities
Kexin Zhao, Jiaojiao Huang, Yue Zhao, et al.
Biochimica et Biophysica Acta (BBA) - Reviews on Cancer (2023) Vol. 1878, Iss. 6, pp. 188983-188983
Closed Access | Times Cited: 23
ATM inhibition augments type I interferon response and antitumor T-cell immunity when combined with radiation therapy in murine tumor models
Won Jong Jin, Luke Zangl, Meredith Hyun, et al.
Journal for ImmunoTherapy of Cancer (2023) Vol. 11, Iss. 9, pp. e007474-e007474
Open Access | Times Cited: 19
Granzyme serine proteases in inflammation and rheumatic diseases
Alexandre Aubert, Karen Jung, Sho Hiroyasu, et al.
Nature Reviews Rheumatology (2024) Vol. 20, Iss. 6, pp. 361-376
Closed Access | Times Cited: 8
Page 1 - Next Page

Scroll to top